Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2231-2241

  Ramadan, Rawi ^a   Faour, Diana ^b   Awad, Hoda ^b   Khateeb, Eleanor ^b   Cohen, Ravit ^b   Yahia, Ali ^a   Torgovicky, Rafael ^c   Cohen, Raanan ^c   Lazari, David ^c   Kawachi, Hiroshi ^d   Abassi, Zaid ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NIIGATA UNIVERSITY   (Japan)

Author keywords

Adriamycin; Clearance; Everolimus; Nephrotic syndrome; Proteinuria; Rat

Indexed keywords

DOXORUBICIN; EVEROLIMUS; NEPHRIN; PODOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL ANIMAL; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CYTOPROTECTION; DOXORUBICIN; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; MALE; MEMBRANE PROTEINS; NEPHROTIC SYNDROME; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS;

EID: 84861906911     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr581     Document Type: Article

References (43)

1. Bertani T, Poggi A, Pozzoni R, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 1982; 46: 16-23
2. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol 1988; 254: R1017-R1024
3. Keeler R, Feuchuk D, Wilson N. Atrial peptides and the renal response to hypervolemia in nephrotic rats. Can J Physiol Pharmacol 1987; 65: 2071-2075
4. Keane WF, Kasiske BL, O'Donnell MP. The role of lipids in progressive glomerular disease. Adv Exp Med Biol 1987; 223: 81-87
5. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011; 16: 30-38
6. Chugh SS, Kaw B, Kanwar YS. Molecular structure-function relationship in the slit diaphragm. Semin Nephrol 2003; 23: 544-555
7. Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W, et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629
8. Tryggvason K, Jaakko Patrakka J, Jorma Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354: 1387-1401
9. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817
10. Doggrell SA. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Expert Opin Pharmacother 2003; 4: 1185-1188
11. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124
12. Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens 2002; 11: 377-381
13. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vivo and in vitro. Transplantation 1997; 64: 36-42
14. Pascual J, Fernandez AM,Marcen R et al. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia-a case report. Nephrol Dial Transplant 2006; 11 (Suppl 3): iii38-iii41
15. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3): iii18-iii23
16. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845-1857
17. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875
18. Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother 2005; 6: 1539-1549
19. Skhiri H, Morelon E, Noel LH et al. Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transpl Int 2005; 18: 458-460
20. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007; 49: 310-317
21. Fervenza FC, Fitzpatrick PM, Mertz J et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19: 1288-1292
22. Wittmann S, Daniel C, Braun A et al. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 2008; 108: e45-e56
23. Tumlin JA, Miller D, Near M et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006; 1: 109-116
24. Tsagalis G, Psimenou E, Iliadis A et al. Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases. Am J Kidney Dis 2009; 54: 340-344
25. Nakhoul F, Khankin E, Yaccob A et al. Eplerenone potentiates the anti-proteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol 2008; 294: F628-F637
26. Nakhoul F, Ramadan R, Khankin E et al. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of anti-proteinuric therapies. Am J Physiol Renal Physiol 2005; 289: F880-F890
27. Holthofer H, Ahola H, Solin ML et al. Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney. Am J Pathol 1999; 155: 1681-1687
28. Yuan H, Takeuchi E, Taylor GA et al. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002; 13: 946-956
29. Vogelbacher R, Wittmann S, Braun A et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499
30. Bonegio RG, Fuhro R, Wang Z et al. Rapamycin ameliorates proteinuriaassociated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072
31. Daniel C, Renders L, Amann K et al. Mechanisms of everolimusinduced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849-2861
32. Inza A, Balda S, Alvarez E et al. Conversion to everolimus in kidney transplant recipients with decreased renal function. Transplant Proc 2009; 41: 2134-2136
33. Morales J, Fierro A, Benavente D et al. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 2007; 39: 591-593
34. Lui SL, Tsang R, Chan KW et al. Rapamycin attenuates the severity of murine adriamycin nephropathy. Am J Nephrol 2009; 29: 342-352
35. Rangan GK, Coombes JD. Renoprotective effects of sirolimus in nonimmune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2007; 22: 2175-2182
36. Daniel C, Ziswiler R, Frey B et al. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000; 8: 52-62
37. Dittrich E, Schmaldienst S, Soleiman A et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17: 215-220
38. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442
39. Doublier S, Ruotsalainen V, Salvidio G et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158: 1723-1731
40. Huh W, Kim DJ, Kim MK et al. Expression of nephrin in acquired human glomerular disease. Nephrol Dial Transplant 2002; 17: 478-484
41. Kawachi H, Koike H, Kurihara H et al. Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 2000; 57: 1949-1961
42. Luimula P, Ahola H, Wang SX et al. Nephrin in experimental glomerular disease. Kidney Int 2000; 58: 1461-1468
43. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78: 1362-1366